Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 74 peer-reviewed journal articles Updated
Hematology · AL Amyloidosis

Understanding AL Amyloidosis (Primary Systemic Amyloidosis)

At a Glance

AL amyloidosis, formerly known as primary systemic amyloidosis, occurs when abnormal plasma cells produce misfolded light chain proteins that build up in organs. It is not inherited. Modern treatments like monoclonal antibodies can halt the disease and allow your organs to heal.

Receiving a diagnosis of AL amyloidosis can feel overwhelming, especially because the name sounds complex and the condition is rare [1]. It is natural to feel anxious when facing a disease you may have never heard of before. This guide is designed to help you understand your diagnosis, advocate for your care, and navigate your treatment options safely and effectively.

What is AL Amyloidosis?

In the past, doctors often called this condition primary systemic amyloidosis. The name was updated to AL amyloidosis to be more scientifically accurate [2][3]:

  • A stands for Amyloid (the abnormal protein deposits).
  • L stands for Light Chain (the specific part of the antibody that is misbehaving).

Inside your bone marrow, cells called plasma cells act as “antibody factories.” In AL amyloidosis, a group of these cells begins producing unstable, misfolded proteins called immunoglobulin light chains [4][2]. These “sticky” light chains clump together to form tough fibers called amyloid fibrils [4]. These fibrils deposit in various organs—most commonly the heart, kidneys, and nerves—acting like “sand in the gears” of your body [4][5].

Unlike some other forms of amyloidosis (such as certain types of ATTR amyloidosis), AL amyloidosis is not an inherited condition, meaning you cannot pass it down to your children [6].

Why You Can Feel Hopeful

While AL amyloidosis is a serious condition, the medical community’s understanding of it has advanced rapidly. Here are three stabilizing facts:

  1. Treatment is more powerful than ever. The introduction of targeted monoclonal antibodies has revolutionized care and significantly improved survival [7][8].
  2. Early “Deep Response” is the goal. Doctors now have clear benchmarks to halt the production of toxic light chains, allowing long-term health and organ recovery [9][10].
  3. Organs can heal. When the “factory” stops producing the toxic proteins, your body can often slowly clear existing amyloid deposits over time [11][12].

Navigating This Guide

To help you advocate for the best possible care, we have broken down the essential information into the following sections:

01

Recognizing Symptoms and Securing an Accurate Diagnosis

Learn to recognize AL amyloidosis symptoms like an enlarged tongue and bruising. Understand the diagnostic process, biopsies, and mass spectrometry typing.

02

Understanding Your Pathology Report and Mayo Staging

Learn how to read your AL Amyloidosis pathology report. Understand Mayo Staging, dFLC, NT-proBNP, and what your bone marrow biopsy results mean for care.

03

Standard of Care: Treatments and Care Teams

Learn about the standard of care for AL amyloidosis. Understand the DARA-CyBorD regimen, stem cell transplant options, and why specialized care matters.

04

Daily Management, Monitoring, and Survivorship

Learn how to manage AL amyloidosis at home. Understand the importance of fluid limits, safe medications, and how doctors monitor your blood and organ response.

Common questions in this guide

What is the difference between AL amyloidosis and primary systemic amyloidosis?
They are the same condition. The medical community updated the name from primary systemic amyloidosis to AL amyloidosis because it more accurately describes the science of the disease, which involves amyloid (A) and light chain (L) proteins.
Can I pass AL amyloidosis down to my children?
No, AL amyloidosis is not an inherited disease. Unlike certain other types of amyloidosis, this specific condition is not genetic, meaning you cannot pass it down to your children.
How is AL amyloidosis treated today?
Treatment focuses on stopping the bone marrow from producing the toxic light chain proteins. Today, doctors primarily use targeted monoclonal antibodies, which have revolutionized care and significantly improved patient survival rates.
Can my organs recover from the amyloid protein deposits?
Yes, organ healing is possible. Once treatment successfully stops the "factory" from making toxic light chains, your body can slowly begin to clear the existing amyloid deposits out of your tissues, allowing your organs to recover over time.
How will my doctor know if my treatment is working?
Your care team will monitor your response to treatment by regularly drawing blood to check your free light chain levels. The goal is to achieve a 'deep response,' meaning the production of harmful proteins has been successfully halted.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Are you in direct communication with an amyloidosis Center of Excellence regarding my care?
  2. 2.What is the exact name and type of the amyloidosis I have, and how was it confirmed?
  3. 3.How often will my blood work be drawn to check my free light chain levels during treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    The clinical features and outcomes of systemic light chain amyloidosis with hepatic involvement.

    Zhao L, Ren G, Guo J, et al.

    Annals of medicine 2022; (54(1)):1226-1232 doi:10.1080/07853890.2022.2069281.

    PMID: 35481407
  2. 2

    Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience.

    Sanchorawala V, Sun F, Quillen K, et al.

    Blood 2015; (126(20)):2345-7 doi:10.1182/blood-2015-08-662726.

    PMID: 26443620
  3. 3

    Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis.

    Rivera Duarte A, Reece D, Li X, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2022; (29(1)):23-30 doi:10.1080/13506129.2021.1978423.

    PMID: 34519603
  4. 4

    Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis.

    Vaxman I, Gertz M

    Acta haematologica 2019; (141(2)):93-106 doi:10.1159/000495455.

    PMID: 30650422
  5. 5

    Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis.

    Schulte T, Chaves-Sanjuan A, Speranzini V, et al.

    Nature communications 2024; (15(1)):6359 doi:10.1038/s41467-024-50686-2.

    PMID: 39069558
  6. 6

    Renal amyloidosis: a new time for a complete diagnosis.

    Feitosa VA, Neves PDMM, Jorge LB, et al.

    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica 2022; (55()):e12284 doi:10.1590/1414-431X2022e12284.

    PMID: 36197414
  7. 7

    Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

    Kastritis E, Palladini G, Minnema MC, et al.

    The New England journal of medicine 2021; (385(1)):46-58 doi:10.1056/NEJMoa2028631.

    PMID: 34192431
  8. 8

    Monoclonal gammopathy of renal significance (MGRS)-related AL amyloidosis complicated by amyloid myopathy: a case report.

    Ono E, Ishii A, Higashi Y, et al.

    BMC nephrology 2021; (22(1)):74 doi:10.1186/s12882-021-02272-7.

    PMID: 33639890
  9. 9

    Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab era.

    Bazarbachi AH, Zanwar S, Hegenbart U, et al.

    HemaSphere 2025; (9(12)):e70276 doi:10.1002/hem3.70276.

    PMID: 41473002
  10. 10

    Single Center Experience of Autologous Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis in Korea.

    Kim HR, Yoon SE, Kim D, et al.

    Clinical lymphoma, myeloma & leukemia 2023; (23(2)):97-103 doi:10.1016/j.clml.2022.10.010.

    PMID: 36464620
  11. 11

    First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience.

    Jeryczynski G, Antlanger M, Duca F, et al.

    ESMO open 2021; (6(2)):100065 doi:10.1016/j.esmoop.2021.100065.

    PMID: 33667762
  12. 12

    A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis.

    Heybeli C, Bentall A, Wen J, et al.

    Kidney international 2021; (99(3)):707-715 doi:10.1016/j.kint.2020.06.036.

    PMID: 32712168

This guide is for informational purposes only and provides a general overview of AL amyloidosis. It does not replace professional medical advice from your treatment team or an amyloidosis Center of Excellence.

Get notified when new evidence is published on Primary systemic amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.